

Synthetic Communications >

An International Journal for Rapid Communication of Synthetic Organic Chemistry

Volume 49, 2019 - Issue 16

✓ Full access

689 41

Views CrossRef citations to date Altmetric

0



Articles

Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles

Pramod S. Phatak, Rajubai D. Bakale, Sambhaji T. Dhumal, Lalita K. Dahiwade,
Prafulla B. Choudhari, Vagolu Siva Krishna, ...show all

Pages 2017-2028 | Received 13 Apr 2019, Published online: 16 May 2019

“ Cite this article  <https://doi.org/10.1080/00397911.2019.1614630>



 Full Article

 Figures & data

 References

 Supplemental

 Citations

 Metrics

 Reprints & Permissions

 View PDF

 View EPUB


Abstract

In a search for safer and potent antitubercular agents, here a library of newly substituted dioxoisoindolinylmethyl-triazolyl-*N*-phenylacetamide derivatives (**5a–l**) has been synthesized via click chemistry approach. All synthesized compounds were evaluated for their antitubercular activity against *Mycobacterium tuberculosis* H₃₇Rv (MTB). Among the screened compounds, **5d**, **5e**, **5h**, and **5l** showed good antitubercular activity. The compounds **5d** and **5l** have shown very effective antitubercular activity against *Mycobacterium tuberculosis* H₃₇Rv (MTB) with MIC 12.5 µg/mL. All the newly synthesized compounds were thoroughly characterized by ¹H NMR, ¹³C

In this article

structure of *Mycobacterium tuberculosis enoyl reductase* to demonstrate the mechanism of antitubercular activity.

GRAPHICAL ABSTRACT



Q KEYWORDS: Antitubercular activity click chemistry molecular docking study N-phenylacetamide phthalimide 1,2,3-triazole

Introduction

According to the World Health Organization (WHO) report on TB, the diseases, namely tuberculosis (TB) caused by the pathogen *Mycobacterium tuberculosis* (MTB) is one of the most deadliest infectious disease. As per Global Tuberculosis Report-2018, it is the leading cause due to a single infectious agent and its percentage is above HIV/AIDS.^[1] Drug-Resistant TB is a major issue of public health. In 2017, WHO estimated that about 558,000 people in the world having TB are resistant to first-line drug rifampicin (RR-TB) and 82% having multi-drug resistant TB (MDR-TB). Treatment for drug-sensitive TB takes up to 2 months and for drug-resistant TB, it may take up to 24 months.^[2] So, there is an urgent need to search for new drugs and their strategies for effective treatment. *Mycobacterium tuberculosis* has a unique cell wall made up of mycolic acids, which are highly lipophilic one. These mycolic acids are the major hurdle for antimycobacterial drug action. Mycolic acids are synthesized in the *Mycobacterium* via fatty acid biosynthesis process. Enoyl-ACP reductase is an important enzyme of the type II fatty acid


In this article

^

system, so it deserves full credentials to act as an utilizable antitubercular target.

The heterocyclic compounds containing phthalimide core are the biologically active species which shows α -glucosidase inhibition,^[3] antimalarial,^[4] anti-inflammatory,^[5] anti-microbial, anti-oxidant,^[6] and anti-angiogenic^[7] activities. Phthalimide when coupled with other heterocyclic groups like sulfonamide group, aminoquinoline, etc. also shows *in vitro* antitubercular activities.^[8-11] Azoles are the important class of nitrogen-containing heterocycles that shows very good biological activities such as antifungal, antibacterial, antimalarial, anti-inflammatory, and antitubercular.^[12,13] Particularly, 1,2,3-triazole is an important class of heterocyclic compounds, which has attracted increasing attention in medicinal chemistry and drug discovery (Figure 1).^[14-16] 1,2,3-Triazoles are synthesized by “Click Chemistry” approach, which was firstly reported by Sharpless and research group.^[17] 1,2,3-Triazole derivatives are endowed with numerous therapeutic activities, such as antimicrobial,^[18] acidic corrosion inhibitor for steel,^[19] SGLT2 inhibitor,^[20] histone deacetylase 1 inhibitor,^[21] α -glucosidase inhibitor,^[22] and antitubercular.^[23]

Figure 1. Some representative examples of 1,2,3-triazoles having antitubercular activity.



Display full size

Results and discussions

Chemistry


Considering the urgent need for preparing a library of new antitubercular agents and highly impressed by the antitubercular activities displayed by 1,2,3-triazoles, here we thought

In this article

acetyl phenoxy acetamide scaffolds in a single molecular framework with the hope to obtain better antimycobacterial activity. Herein, we have reported new dioxoisindolinylmethyl-triazolyl-*N*-phenylacetamides (**5a-l**) via “Click Chemistry” approach. All the synthesized derivatives were evaluated for their antitubercular activity against *Mycobacterium tuberculosis* H₃₇Rv and determined their MIC (minimum inhibitory concentration) values. Molecular docking study and *in silico* ADME predictions of the synthesized compounds have been performed and results are incorporated.

In the present study, we have reported the synthesis of substituted 2-(4-((1,3-dioxoisindolin-2-yl)methyl)-1*H*-1,2,3-triazol-1-yl)-*N*-phenylacetamides (**5a-l**) starting from phthalimide via click chemistry approach. Firstly, we performed the reaction of phthalimide (**1**) and propargyl bromide (**2**) in the presence of K₂CO₃ in DMF at room temperature to obtain 2-(prop-2-ynyl)isindoline-1,3-dione (**3**) (Scheme 1) with 90% yield.^[24-26] The structure of 2-(prop-2-ynyl)isindoline-1,3-dione (**3**) was confirmed by spectral data. Further, the reaction of compound 2-(prop-2-ynyl)isindoline-1,3-dione (**3**) and freshly prepared substituted *N*-phenyl acetamides (**4a-l**) were carried out in the presence of CuSO₄·5H₂O and sodium ascorbate in PEG-400 at room temperature and to furnish the corresponding substituted 2-(4-((1,3-dioxoisindolin-2-yl)methyl)-1*H*-1,2,3-triazol-1-yl)-*N*-phenylacetamides (**5a-l**) with 75–90% yields (Scheme 2). The physical data of 1,2,3-triazoles is incorporated in Table 1.

Scheme 1. Synthesis of 2-(prop-2-ynyl)isindoline-1,3-dione (**3**).




Display full size

Scheme 2. Synthesis of substituted 2-(4-((1,3-dioxoisindolin-2-yl)methyl)-1*H*-1,2,3-triazol-1-yl)-*N*-phenylacetamides (**5a-l**).

In this article

^



Display full size

Table 1. Physical data and MIC values of substituted 2-(4-((1,3-dioxisoindolin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-phenylacetamides (**5a-l**).



Display Table

All the newly synthesized compounds have been characterized using their IR, ¹H NMR, ¹³CNMR, and HRMS spectral data. In IR spectrum of compound (**5a**), the characteristic peak at 1540 cm⁻¹ indicates the presence of C=N bond. The ¹H NMR spectrum of compound (**5a**) displays a singlet at δ 2.32 ppm due to the CH₃ attached to the aromatic ring. The characteristic peaks of two singlets at δ 5.02 and 5.23 ppm confirms the presence of two CH₂ groups. The singlet at δ 7.96 ppm confirms the presence of 1,2,3-triazole ring in compound (**5a**). The three characteristic peaks in the ¹³CNMR spectrum of (**5a**) in the upfield region at δ 28.26, 31.83, and 51.47 ppm confirm the presence of one CH₃ and two CH₂ carbons, respectively. The signals observed at δ 162.41 and 166.23 ppm clearly indicates the presence of two carbonyl groups of N-phenylacetamide and phthalimide, respectively. The HRMS spectrum further strengthens the structure assigned to 2-(4-((1,3-dioxisoindolin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(p-tolyl)acetamide (**5a**) as it displays [M + H]⁺ ion peak at m/z 376.1410 for the molecular formula C₂₀H₁₇N₅O₃.

Antitubercular activity

The inoculum was prepared from fresh LJ medium re-suspended in 7H9-S medium (7H9 broth, 0.1% casitone, 0.5% glycerol, supplemented oleic acid, albumin, dextrose, and catalase [OADC]), adjusted to OD₅₉₀ 1.0, and diluted 1:20; 100 μl was used as an inoculum. Each drug stock

In this article



Serial two-fold dilutions of each drug were prepared directly in a sterile 96-well microtiter plate using 100 μ l 7H9-S. A growth control containing no antibiotic and a sterile control was also prepared on each plate. Sterile water was added to all perimeter wells to avoid evaporation during the incubation. The plate was covered, sealed in plastic bags, and incubated at 37 °C in a normal atmosphere. After 7 days of incubation, 30 μ l of Alamar blue solution was added to each well and the plate was re-incubated overnight. A change in color from blue (oxidised state) to pink (reduced) indicated the growth of bacteria and the MIC was defined as the lowest concentration of drug that prevented this change in color.^[27] The compounds **5d**, **5e**, **5h**, and **5i** showed notable antitubercular activity with MIC values 12.5, 25, 25, and 12.5 μ g/mL, respectively (Table 1). It has been observed that the compounds having 4-bromo (**5d**) or 2-methyl (**5i**) substituents on aromatic ring are showing very good antitubercular activities. Also, 3-nitro (**5e**) or 4-fluoro (**5h**) substituents are useful for possessing antitubercular activities.

Docking analysis

Docking analysis was utilized to predict the mechanism of action of the designed derivatives for antimycobacterial potential. All the molecules exhibited binding energies in the range of -92.69 to -112.27 kcal/mol. Most active molecules (**5d**) exhibited hydrogen bond interactions with TYR158 and MET199, showed aromatic interaction with TYR158, hydrophobic interaction with MET199, TYR158 and Van der Waals interactions with PHE97, MET98, MET103, GLY104, PHE149, PRO156, ALA157, TYR158, MET161, ILE202, LEU207, ALA211, ILE215 (Figure 2). The compound (**5i**) showed hydrogen bond interactions with TYR158 showed aromatic interaction with TYR158 and PHE149 hydrophobic interaction with GLY96, PHE97, MET98, MET161, MET199, and Vander Waals interactions with PHE97, MET98, MET103, GLY104, PHE149, PRO156, ALA157, TYR158, MET161, ILE202, LEU207, ALA211, ILE215 (Figure 3). The compound (**5e**) showed hydrogen bond interactions with TYR158, GLY104, showed aromatic interaction with PHE149, TYR158 hydrophobic interaction with PHE149, LYS165, PRO193, MET199, LEU218, and Van der Waals interactions with GLY96, PHE97, MET98, MET103, GLY104, PHE149, PRO156, ALA157, TYR158, MET161, ALA198, ILE202, LEU207, ALA211, and ILE215 (Figure 4). The compound (**5h**) showed hydrogen bond interactions with TYR158, showed aromatic interaction with PHE149, TYR158 hydrophobic interaction with PHE149, PRO193, and Van der Waals interactions with PHE97, MET98, MET103, GLY104, PHE149, PRO156, ALA157, TYR158, MET161, ALA198, ILE202, LEU207, ALA211, and ILE215 (Figure 5).

Table 2. Physicochemical property prediction of substituted 2-(4-((1,3-dioxisoindolin-2-yl)methyl)-1*H*-1,2,3-triazol-1-yl)-*N*-phenylacetamides (**5a-l**).



[Download CSV](#) [Display Table](#)

Conclusions

In conclusion, we have reported a series of newly substituted dioxisoindolinylmethyl-triazolyl-*N*-phenylacetamide derivatives by 1,3-dipolar cycloaddition of the alkyne (**3**) and substituted phenyl acetamides (**4a-l**). Amongst the synthesized 1,2,3-triazoles, the compounds **5d**, **5e**, **5h**, and **5l** have displayed notable antitubercular activity against *Mycobacterium tuberculosis* H₃₇Rv. Molecular docking study indicates that all the molecules are binding to the *enoylreductase* of the *Mycobacterium tuberculosis*. We think the results obtained herein will provide a strong platform for structure-based optimization of these newly identified 1,4-disubstituted 1,2,3-triazole derivatives as antitubercular agents.

Experimental

The chemicals used were of laboratory grade. Melting points of all the synthesized compounds were determined in open capillary tubes and are uncorrected. The IR spectra (KBr pellets) were recorded on Bruker FT-IR spectrometer. ¹H NMR spectra were recorded on a Bruker DRX-300 MHz NMR spectrometer using tetramethylsilane (TMS) as an internal standard and chemical shifts are in δ (ppm). ¹³C NMR spectra were recorded on a Bruker DRX-75 MHz NMR in CDCl₃ + DMSO-*d*₆. High-resolution mass spectra (HRMS) were obtained using the Agilent 6520 (Q-TOF) ESI-HRMS instrument. The purity of the title and intermediate compounds was checked by thin-layer chromatography (TLC).

Synthesis of 2-(prop-2-yn-1-yl)isoindoline-1,3-dione (**3**)

A mixture of phthalimide (**3**) (0.01 mol), propargyl bromide (0.01 mol), and K₂CO₃ (0.02 mol) was

completion of the reaction, the reaction mixture was poured on crushed ice. The solid obtained was filtered, washed with water, and recrystallized from ethanol.

Yield: 90%, M.P.: 151–153 °C; White Solid. ^1H NMR (300 MHz, CDCl_3 + $\text{DMSO-}d_6$) δ ppm = 3.17 (s, 1H), 4.43 (d, J = 3 Hz, 2H), 7.78–7.83 (m, 2H), 7.85–7.90 (m, 2H).

General procedure for the synthesis of 2-(4-((1,3-dioxoisindolin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-phenylacetamides (5a-l)

2-(Prop-2-yn-1-yl)isoindoline-1,3-dione (**3**) (0.01 mol) and substituted *N*-phenylacetamides (**4a-l**) (0.01 mol) were stirred in the presence of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (20 mol%) and sodium ascorbate (20 mol%) in PEG-400. The progress of the reactions was monitored by TLC. After completion of reactions (5–6 h), the reaction mixtures were poured in ice cold water. The products obtained were filtered, washed with water, and recrystallized from ethanol.

2-(4-((1,3-Dioxoisindolin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(*p*-tolyl)acetamide (5a): Yield: 90%, M.P.: 240–242 °C; White Solid; IR (KBr) ν cm^{-1} : 3270, 3147, 3052, 2333, 1692, 1667, 1540, 1396, 1335, 1091, 818, 711; ^1H NMR (300 MHz, CDCl_3 + $\text{DMSO-}d_6$) δ ppm = 2.32 (s, 3H), 5.02 (s, 2H), 5.23 (s, 2H), 7.12 (d, J = 9 Hz, 2H), 7.47 (d, J = 9 Hz, 2H), 7.74–7.78 (m, 2H), 7.83–7.87 (m, 2H), 7.96 (s, 1H), 10.01 (s, 1H); ^{13}C NMR (75 MHz, CDCl_3 + $\text{DMSO-}d_6$) δ ppm = 28.26, 31.83, 51.47, 118.51, 122.11, 123.69, 128.08, 130.70, 132.18, 133.13, 134.53, 141.17, 162.41, 166.23; HRMS (ESI) $^+$ calcd. for $\text{C}_{20}\text{H}_{17}\text{N}_5\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 376.1365 and found 376.1410.

Docking analysis

Molecular docking analysis was performed to predict the possible mode of action of the synthesized triazole derivatives. Crystal structure of *Mycobacterium tuberculosis enoylreductase* (INHA) complexed with *N*-(3-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide (PDB ID: 4TZT) was *enoylreductase* downloaded from the free protein database www.rcsb.org. Crystal structure of the download was refined via removal of the water and addition of the hydrogen atoms so that native geometry of the protein is achieved. Ligands were prepared in Vlife engine module and optimized via the Merck molecular force field. Biopredicta module of the V life MDS 4.3 was utilized for docking analysis.^[28-32] ADME of the synthesized derivatives was predicted from the free online server <http://www.swissadme.ch>.^[33-35]

Supporting material to this article containing spectral data, ^1H and ^{13}C NMR spectrums and docking images of synthesized compounds are available for the authorized users.

Supplemental material

Supplemental Material

 Download MS Word (4.4 MB)

Acknowledgement

Authors are thankful to Professor R. A. Mane for his invaluable discussions and guidance. Authors are also very much grateful to Birla Institute of Technology and Science-Pilani, Hyderabad Campus for providing screening data of synthesized compounds.

Additional information

Funding

One of the authors, PHATAK PRAMOD SHAHAJEE has received UGC Junior Research Fellowship (JRF). The Sr. No. 2061410333 and Ref. No. 22/06/2014 (i) EU-V.

References

1. World Health Organization (WHO). *WHO Global Tuberculosis Report 2018*; WHO: Geneve, Switzerland, 2018. http://www.who.int/tb/publications/global_report/en/
[Google Scholar](#)

In this article



2. Jnawali, H. N.; Ryoo, S. Tuberculosis: Current Issues in Diagnosis and Management 2013. DOI: 10.5772/54960.

| [Google Scholar](#)

3. Bian, X.; Wang, Q.; Ke, C.; Zhao, G.; Li, Y. A New Series of N-2-Substituted-5-(p-Toluenesulfonylamino)Phthalimide Analogues as α -Glucosidase Inhibitors. *Bioorg. Med. Chem. Lett.* 2013, **23**, 2022. DOI: 10.1016/j.bmcl.2013.02.011.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

4. González, M. A.; Clark, J.; Connelly, M.; Rivas, F. Antimalarial Activity of Abietane Ferruginol Analogues Possessing a Phthalimide Group. *Bioorg. Med. Chem. Lett.* 2014, **24**, 5234–5237. DOI: 10.1016/j.bmcl.2014.09.061.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

5. Machado, A. L.; Lima, L. M.; Araújo, J. X.; Jr, Fraga, C. A. M.; Koatz, V. L. G.; Barreiro, E. J. Design, Synthesis and Antiinflammatory Activity of Novel Phthalimide Derivatives, Structurally Related to Thalidomide. *Bioorg. Med. Chem. Lett.* 2005, **15**, 1169–1172. DOI: 10.1016/j.bmcl.2004.12.012.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

6. Lamie, P.; Philoppes, J.; El-Gendy, A.; Rarova, L.; Gruz, J. Design, Synthesis and Evaluation of Novel Phthalimide Derivatives as in Vitro Anti-Microbial, Anti-Oxidant and Anti-Inflammatory Agents. *Molecules.* 2015, **20**, 16620–16642. DOI: 10.3390/molecules200916620.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

7. Nagarajan, S.; Majumder, S.; Sharma, U.; Rajendran, S.; Kumar, N.; Chatterjee, S.; Singh, B. Synthesis and anti-Angiogenic Activity of Benzothiazole, Benzimidazole Containing Phthalimide Derivatives. *Bioorg. Med. Chem. Lett.* 2013, **23**, 287–290. DOI: 10.1016/j.bmcl.2012.10.106.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

8. Alotaibi, H.; Karamalshakhi, J.; Bask, D.; Kumar, J.; Sarbajit, C.; Ökten, C.; Kocaşen, T. Synthesis

In this article



4149–4154. DOI: 10.1016/j.bmc.2012.04.060.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

9. Rani, A.; Viljoen, A.; Kremer, L.; Kumar, V. Microwave-Assisted Highly Efficient Route to 4-Aminoquinoline-Phthalimide Conjugates: Synthesis and Anti-Tubercular Evaluation. *ChemistrySelect*. 2017, **2**, 10782–10785. DOI: 10.1002/slct.201702220.

[Web of Science®](#) | [Google Scholar](#)

10. Santos, J. L.; Yamasaki, P. R.; Chin, C. M.; Takashi, C. H.; Pavan, F. R.; Leite, C. Q. Synthesis and in Vitro anti Mycobacterium tuberculosis Activity of a Series of Phthalimide Derivatives. *Bioorg. Med. Chem.* 2009, **17**, 3795–3799. DOI: 10.1016/j.bmc.2009.04.042.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

11. Kushwaha, N.; Tripathi, A.; Kushwaha, S. K. S. Synthesis, Characterization and in Vitro anti Mycobacterium tuberculosis Evaluation of Some Novel Phthalimide Derivatives. *Der Pharma Chemica*. 2014, **6**, 188–196.

[Google Scholar](#)

12. Ashok, D.; Chiranjeevi, P.; Kumar, A. V.; Sarasija, M.; Krishna, V. S.; Sriram, D.; Balasubramanian, S. 1,2,3-Triazole-Fused Spirochromenes as Potential anti-Tubercular Agents: Synthesis and Biological Evaluation. *RSC Adv*. 2018, **8**, 16997. DOI: 10.1039/C8RA03197E.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

13. Gao, F.; Yang, H.; Lu, T.; Chen, Z.; Ma, L.; Xu, Z.; Schaffer, P.; Lu, G. Design, Synthesis and Anti-Mycobacterial Activity Evaluation of Benzofuran-Isatin Hybrids. *Eur. J. Med. Chem.* 2018, **159**, 277–281. DOI: 10.1016/j.ejmech.2018.09.049.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

14. Naik, R. J.; Kulkarni, M. V.; Pai, K. S. R.; Nayak, P. G. Click Chemistry Approach for Bis-Chromenyl Triazole Hybrids and Their Antitubercular Activity. *Chem. Biol. Drug Des.* 2012, **80**, 516–523. DOI: 10.1111/j.1747-0285.2012.01441.x

In this article



15. Shaikh, M. H.; Subhedar, D. D.; Khan, F. A. K.; Sangshetti, J. N.; Nawale, L.; Arkile, M.; Sarkar, D.; Shingate, B. B. Synthesis of Novel Triazole-Incorporated Isatin Derivatives as Antifungal, Antitubercular, and Antioxidant Agents and Molecular Docking Study. *J. Heterocyclic Chem.* 2017, **54**, 413–421. DOI: 10.1002/jhet.2598.

[Web of Science ®](#) | [Google Scholar](#)

16. Sajja, Y.; Vanguru, S.; Vulupala, H. R.; Bantu, R.; Yogeswari, P.; Sriram, D.; Nagarapu, L. Design, Synthesis and in Vitro Anti-Tuberculosis Activity of Benzo [6,7]Cyclohepta[1,2-b]Pyridine-1,2,3-Triazole Derivatives. *Bioorg. Med. Chem. Lett.* 2017, **27**, 5119–5121. DOI: 10.1016/j.bmcl.2017.10.071.

[PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

17. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. *Angew. Chem.* 2002, **114**, 2708. DOI: 10.1002/1521-3757(20020715)114:14<2708::AID-ANGE2708>3.0.CO;2-0.

[Google Scholar](#)

18. Kushwaha, K.; Kaushik, N. L.; Jain, S. C. Design and Synthesis of Novel 2H-Chromen-2-One Derivatives Bearing 1,2,3-Triazole Moiety as Lead Antimicrobials. *Bioorg. Med. Chem. Lett.* 2014, **24**, 1795–1801. DOI: 10.1016/j.bmcl.2014.02.027.

[PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

19. Gonzalez-Olvera, R.; Espinoza-Vázquez, A.; Negrón-Silva, G.; Palomar-Pardavé, M.; Romero-Romo, M.; Santillan, R. Multicomponent Click Synthesis of New 1,2,3-Triazole Derivatives of Pyrimidine Nucleobases: Promising Acidic Corrosion Inhibitors for Steel. *Molecules.* 2013, **18**, 15064–15079. DOI: 10.3390/molecules181215064.

[PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

20. Li, L. T.; Zhou, L. F.; Li, Y. J.; Huang, J.; Liu, R. H.; Wang, B.; Wang, P. Facile Synthesis of 1,2,3-Triazole Analogs of SGLT2 Inhibitors by ‘Click Chemistry’. *Bioorg. Med. Chem. Lett.* 2012, **22**, 642–644. DOI: 10.1016/j.bmcl.2011.10.062

In this article

^

21. Sun, Q.; Yao, Y.; Liu, C.; Li, H.; Yao, H.; Xue, X.; Liu, J.; Tu, Z.; Jiang, S. Design, Synthesis, and Biological Evaluation of Novel Histone Deacetylase 1 Inhibitors through Click Chemistry. *Bioorg. Med. Chem. Lett.* 2013, **23**, 3295–3299. DOI: 10.1016/j.bmcl.2013.03.102.
[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)
22. Wang, G.; Peng, Z.; Wang, J.; Li, J.; Li, X. Synthesis and Biological Evaluation of Novel 2,4,5-Triarylimidazole-1,2,3-Triazole Derivatives via Click Chemistry as α -Glucosidase Inhibitors. *Bioorg. Med. Chem. Lett.* 2016, **26**, 5719–5723. DOI: 10.1016/j.bmcl.2016.10.057.
[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)
23. Anand, A.; Kulkarni, M. V.; Joshi, S. D.; Dixit, S. R. One Pot Click Chemistry: A Three Component Reaction for the Synthesis of 2-Mercaptobenzimidazole Linked Coumarinyl Triazoles as anti-Tubercular Agents. *Bioorg. Med. Chem. Lett.* 2016, **26**, 4709–4713. DOI: 10.1016/j.bmcl.2016.08.045.
[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)
24. da Silva, M. T.; de Oliveira, R. N.; Valença, W. O.; Barbosa, F. C. G.; da Silva, M. G.; Camara, C. A. Synthesis of N-Substituted Phthalimidoalkyl 1H-1,2,3-Triazoles: A Molecular Diversity Combining Click Chemistry and Ultrasound Irradiation. *J. Braz. Chem. Soc.* 2012, **23**, 1839–1843. DOI: 10.1590/S0103-50532012005000053.
[Web of Science®](#) | [Google Scholar](#)
25. da Silva, G. B.; Guimaraes, B. M.; Assis, S. P. O.; Lima, V. L. M.; de Oliveira, R. N. Ultrasound-Assisted Synthesis of 1-N- β -D-Glucopyranosyl-1H-1,2,3-Triazole Benzoheterocycles and Their Anti-Inflammatory Activities. *J. Braz. Chem. Soc.* 2013, **24**, 914–921. DOI: 10.5935/0103-5053.20130117.
[Web of Science®](#) | [Google Scholar](#)
26. Lopez-Gonzalez, R.; Bautista-Renedo, J.; Martinez-Otero, D.; Reyes, H.; González-Rivas, N.; Cuevas-Yanez, E. 1,4- and 1,5-di(N-Phthalimidomethyl)-1,2,3-Triazoles: crystal Structures and Density Functional Theory Studies of the Alkyne and Azide Precursors. *J. Chem. Res.* 2016, **40**, 208–212. DOI: 10.3181/174751916X14608006114015

27. Collins, L. A.; Franzblau, S. G. Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compounds against *Mycobacterium tuberculosis* and *Mycobacterium avium*. *Antimicrob. Agents Chemother.* 1997, *41*, 1004–1009. DOI: 10.1128/AAC.41.5.1004.
[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)
28. Gjorgjieva, M.; Tomasic, T.; Barancokova, M.; Katsamakos, S.; Iilas, J.; Tammela, P.; Peterlin Masic, L.; Kikelj, D. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. *J. Med. Chem.* 2016, *59*, 8941–8954. DOI: 10.1021/acs.jmedchem.6b00864.
[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)
29. Kamat, S. R.; Salunkhe, R. S.; Choudhari, P. B.; Dhavale, R. P.; Mane, A. H.; Lohar, T. R. Efficient Synthesis of Chromeno[2,3-c]Pyrazolyl-Pyrazolol in Hydrotropic Solution and Their anti-Infective Potential. *Res. Chem. Intermed.* 2018, *44*, 1351–1362. DOI: 10.1007/s11164-017-3171-5.
[Web of Science®](#) | [Google Scholar](#)
30. Abhale, Y. K.; Shinde, A. D.; Deshmukh, K. K.; Nawale, L.; Sarkar, D.; Choudhari, P. B.; Kumbhar, S. S.; Mhaske, P. C. Synthesis, Antimycobacterial Screening and Molecular Docking Studies of 4-Aryl-4'-Methyl-2'-Aryl-2,5'-Bisthiazole Derivatives. *Med. Chem. Res.* 2017, *26*, 2889–2899. DOI: 10.1007/s00044-017-1988-5.
[Web of Science®](#) | [Google Scholar](#)
31. Kondhare, D. D.; Gyananath, G.; Tamboli, Y.; Kumbhar, S. S.; Choudhari, P. B.; Bhatia, M. S.; Zubaidha, P. K. An Efficient Synthesis of Flavanones and Their Docking Studies with Aldose Reductase. *Med. Chem. Res.* 2017, *26*, 987–998. DOI: 10.1007/s00044-017-1813-1.
[Web of Science®](#) | [Google Scholar](#)
32. Deodware, S. A.; Sathe, D. J.; Choudhari, P. B.; Lokhande, T. N.; Gaikwad, S. H. Development and Molecular Modeling of Co(II), Ni(II) and Cu(II) Complexes as High Acting Antibreast Cancer Agents. *Arab. J. Chem.* 2017, *10*, 262–272. DOI: 10.1016/j.arabjc.2016.09.024.
[Web of Science®](#) | [Google Scholar](#)

33. Daina, A.; Michielin, O.; Zoete, V. Swiss ADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. *Sci. Rep.* 2017, *7*, 42717. DOI: 10.1038/srep42717.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

34. Daina, A.; Michielin, O.; Zoete, V. iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach. *J. Chem. Inf. Model.* 2014, *54*, 3284–3301. DOI: 10.1021/ci500467k.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

35. Daina, A.; Michielin, O.; Zoete, V. A Boiled-Egg to Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. *Chem. Med. Chem.* 2016, *11*, 1117–1121.

[Web of Science®](#) | [Google Scholar](#)

[Download PDF](#)

Related research

[People also read](#)



[Recommended articles](#)

[Cited by](#)

41

In this article



Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright © 2024 Informa UK Limited [Privacy policy](#) [Cookies](#) [Terms & conditions](#)



[Accessibility](#)

Registered in England & Wales No. 3099067
5 Howick Place | London | SW1P 1WG

In this article

